PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
11002234-8	2000	Similarly, after the administration of the first weekly dose of docetaxel, the absolute number of total lymphocytes, CD3(+), CD4(+), and CD8(+) cells was decreased.	Docetaxel	64-73	CD8a molecule	Homo sapiens	137-140	
30744691-0	2019	Cancer-cell-secreted CXCL11 promoted CD8+ T cells infiltration through docetaxel-induced-release of HMGB1 in NSCLC.	Docetaxel	71-80	CD8a molecule	Homo sapiens	37-40	
30744691-4	2019	Functional experiments were carried out to check whether docetaxel (DOC), a chemotherapeutic agent, modifies the expression of HMGB1 and CXCL11, and influences the infiltration properties of CD8+ T cells to the tumor microenvironment.	Docetaxel	57-66	CD8a molecule	Homo sapiens	191-194	
30744691-4	2019	Functional experiments were carried out to check whether docetaxel (DOC), a chemotherapeutic agent, modifies the expression of HMGB1 and CXCL11, and influences the infiltration properties of CD8+ T cells to the tumor microenvironment.	Docetaxel	68-71	CD8a molecule	Homo sapiens	191-194	
30744691-12	2019	CONCLUSIONS: Our results demonstrate that DOC induces CD8+ T cell recruitment to the tumor microenvironment by enhancing the secretion of HMGB1 and CXCL11, thus improving the anti-tumor efficacy, indicating that modulating the HMGB1-CXCL11 axis might be helpful for NSCLC treatment.	Docetaxel	42-45	CD8a molecule	Homo sapiens	54-57	
29615076-0	2018	Use of the tumor-infiltrating CD8 to FOXP3 lymphocyte ratio in predicting treatment responses to combination therapy with pertuzumab, trastuzumab, and docetaxel for advanced HER2-positive breast cancer.	Docetaxel	151-160	CD8a molecule	Homo sapiens	30-33